Effects of liraglutide on hemodynamic parameters in patients with heart failure

Jin Ying Zhang¹, Xin Yun Wang¹ and Xiang Wang¹

¹Department of Emergency, Binzhou Medical University Hospital, Binzhou, Shandong, China

Correspondence to: Jin Ying Zhang, email: zjy181@126.com

Keywords: glucagon-like peptide-1, heart failure, hemodynamic, pulse indicator continuous cardiac output, left ventricular function

Received: October 19, 2016 Accepted: June 02, 2017 Published: June 19, 2017

ABSTRACT
Glucagon-like peptide-1 analogues improve left ventricular function in patients with acute myocardial infarction. This study aimed to evaluate the effects of liraglutide on hemodynamic parameters in patients with heart failure. A total of 78 patients with heart failure were enrolled in this study between August 2014 and November 2015. Of these, 52 patients were randomized 1:1 to receive either liraglutide or placebo for 7 days. Hemodynamic measurements were made using transpulmonary thermodilution and arterial pulse contour analysis. At 7 days, the difference in change of the primary endpoint of cardiac output between the liraglutide group and control group was +1.1 L/min (95% CI +0.1 to +2.2; P < 0.001). Stroke volume was significantly higher in the liraglutide group compared with the control group (difference: +14.6 ml; P < 0.001). The difference in an increase in the left ventricular contractile index after 7 days of treatment was +210.7 mmHg/s (liraglutide versus control, 95% CI −92.1 to +501.5; P < 0.001). Liraglutide causes favorable changes in markers of inflammation and oxidative stress. Glucagon-like peptide-1 may be associated with improvement in left ventricular function in patients with heart failure. These findings need to be confirmed by larger invasive trials.

INTRODUCTION
Heart failure (HF) is a major cause of morbidity and mortality worldwide [1]. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that reduces plasma glucose, and has direct effects on the cardiovascular system [2]. Several studies have investigated short-term and longer-term effects of GLP-1 in HF [3, 4]. Recently, two large trials evaluated the effect of liraglutide in HF. Neither LIVE nor FIGHT could demonstrate a positive effect of liraglutide in HF [5, 6]. In both of these studies, more serious adverse cardiovascular events were observed in the liraglutide group compared to the control group. Pulse indicator continuous cardiac output (PiCCO) technology is a combination of transpulmonary thermodilution and pulse contour analysis. This technology measures hemodynamic variables (cardiac output, left ventricular ejection fraction and volume) in a fast and feasible way. This study aimed to evaluate the effects of liraglutide on hemodynamic variables in patients with HF using the PiCCO system.

MATERIALS AND METHODS

Study site and ethics
This was a single-center, prospective, interventional study that was conducted at the Binzhou Medical University Hospital, China. The study was approved by the Binzhou Ethics Association and the Ethics Committee of the Binzhou Medical University Hospital, and complied with the Helsinki Declaration. All of the subjects provided written informed consent to participate in the study. The trial was registered at ClinicalTrials.gov (registration number: NCT02490176).

Study population
The study was conducted between August 2014 and November 2015. Patients with HF were eligible for inclusion in the study. Diagnosis of HF was based on an impaired ejection fraction (< 50%) [7]. Patients were
also excluded for the following reasons: unconscious at presentation, valvular heart disease, cardiogenic shock, hypoglycaemia, diabetic ketoacidosis, and renal insufficiency.

**Definitions**

Hypertension was defined as blood pressure ≥ 140/90 mmHg or a history of antihypertensive drug use. Diabetes was defined as a fasting blood glucose level ≥ 7 mmol/L or a history of using oral hypoglycemic drugs or insulin. Hypoglycemia was defined as plasma glucose level ≤ 3.9 mmol/L [8]. The estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula [9] and renal insufficiency was defined as an estimated glomerular filtration rate of < 60 mL/min/1.73 m² [10].

**Experimental treatment protocol**

All patients were informed of potential risks (hypoglycaemia, pancreatitis, nausea) [11] associated with GLP-1 analogues and were then required to submit written informed consent prior to being included in the study. Patients were treated with stable doses of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor agonists, and diuretics at least 3 months prior to randomization. Patients were randomized using a computer-generated sequence to either placebo or liraglutide at a 1:1 ratio. Investigators, participants, and other study personnel were blinded to the assigned treatment for the duration of the study. Patients in the liraglutide group were treated with subcutaneous liraglutide (Novo Nordisk, Bagsvaerd, Denmark), while patients in the control group were provided subcutaneous placebo (Novo Nordisk). After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 days, 1.2 mg liraglutide for another 2 days, and then 1.8 mg liraglutide for 3 days. Such dosages corresponded to 1.6, 3.2, and 4.8 pmol/kg/min, respectively, as referred for an ideal 70 kg patient. Each patient received seven injections of liraglutide or placebo. Immediately after admission, the patients received the first injection of test drug. An oral glucose tolerance test was performed before discharge (usually on day 6). Because the patients were treated with an off-label drug, Good Clinical Practice training was required for all personnel who were involved in the trial.

**Study outcomes**

The primary efficacy endpoint was the effect of liraglutide on cardiac output (CO) at 7 days compared with placebo. Secondary efficacy endpoints included the effects of liraglutide on mean arterial pressure (MAP), the cardiac index (CI), stroke volume (SV), global end systolic volume index (GEDVI), the left ventricular contractile index (dPmx), central venous pressure, serum high-sensitivity C-reactive protein (hsCRP) levels, malondialdehyde levels, and nitric oxide (NO) levels.

**Laboratory tests**

Blood samples were collected and analyzed in the Department of Clinical Biochemistry according to the department's clinical standards. The laboratory data were obtained at admission and at 7 days. Blood samples were analyzed within 2 h after collection. N-terminal pro-B-type natriuretic peptide levels were determined by enzyme immunoassay (Shionoria, Osaka, Japan). The intra-assay coefficient of variation [CV] was 1.3% and the inter-assay CV was 2.3% (normal range, < 150 pg/mL). Levels of hsCRP were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) (R&D Systems Inc., Minneapolis, MN, USA). The intra-assay CV was 3.2% and the inter-assay CV was 3.1% (normal range, < 0.8 mg/dL). Serum interleukin-6 concentrations were measured using an ELISA (R&D Systems Inc., Minneapolis, MN, USA). The intra-assay CV was 2.5% and the inter-assay CV was 4.3%, (normal range, < 8 pg/mL). Superoxide dismutase (SOD) activity was estimated as inhibition of a colorimetric reaction using an assay kit (Cayman Chemicals, Ann Arbor, MI, USA). The intra-assay CV was 4.3% and the inter-assay CV was 5.1% (normal range, 129–216 U/mL). Serum malondialdehyde levels were measured using a thiobarbituric acid-reactive substance method [12] The pink adduct formed by samples was extracted in n-butanol. Each sample was placed in a 96-well plate and read at 535 nm in a microplate spectrophotometer reader (Benchmark Plus, Bio-Rad, Hercules, CA, USA). The intra-assay CV was 2.2% and the inter-assay CV was 4.1% (normal range, 3.46–4.66 nmol/mL). Plasma NO levels were estimated by measuring the levels of nitrate and nitrite as markers of NO bioavailability using a nitrate and nitrite colorimetric assay (Cayman Chemicals). The intra-assay CV was 2.4% and the inter-assay CV was 3.1% (normal range, 28–50 μmol/L). Nitric oxide synthase (NOS) activity was determined using a NOS colorimetric assay (Cayman Chemicals). The intra-assay CV was 2.5% and the inter-assay CV was 3.5% (normal range, 4.93–5.35 U/mL).

**PiCCO**

All patients were equipped with a central venous catheter (jugular or subclavian) and a 4-F thermostortipped arterial catheter (PV2015L13; Pulsion Medical Systems, Munich, Germany), which was inserted into the left femoral artery and advanced to the abdominal aorta. CO, the CI, and the GEDVI were determined discontinuously by thermodilution using a triplicate injection of 15 ml of ice-cold saline that was administered...
through the central venous catheter. This method has also been described in detail elsewhere [13] A continuous CO catheter was inserted for 7 days and this procedure was clearly explained to the patients. All of the patients were at rest, in the decubitus position all of the time. All measurements by PiCCO were undertaken by two investigators who were both blinded to randomization.

**Reproducibility**

To determine the reproducibility of the hemodynamic parameters, 20 randomly selected patients were analyzed by two independent blinded observers. The correlation coefficients of interobserver variability for CO, the CI, and SV were 0.92, 0.90, and 0.94, respectively. The correlation coefficients of intraobserver variability for CO, the CI, and SV were 0.91, 0.88, and 0.93, respectively.

**Clinical follow-up**

There was a pre-specified outpatient follow-up visit per protocol at 3 months. Follow-up information on the study population was obtained during a visit by patients to the outpatient clinic or from a review of the medical records. Follow-up was completed for all patients (follow-up rate of 100%). Major adverse cardiovascular events (MACE) were defined as non-fatal myocardial infarction, hospitalization for heart failure, and cardiac death.

**Statistical analysis**

In a pilot study, a difference in CO was detected between the liraglutide and control groups at 7 days (1.2 ± 1.3 l/min, n = 22). We assumed an average difference in CO between the liraglutide and placebo groups of 1.2 l/min (SD = 1.3). We estimated a sample size of 44 subjects in each study group to achieve a power of 90% to demonstrate superiority of the liraglutide arm over the control arm in the primary endpoint with two-tailed α < 0.05. On the assumption that approximately 90% of randomized patients would complete the trial, we planned to recruit 50 patients (25 patients per group).

Continuous variables are expressed as mean ± standard deviation. Baseline characteristics were compared between the two groups using the independent t test for continuous variables and the χ² test for categorical variables. Differences in changes between the two groups were compared using the independent t test for normally distributed variables or the Mann–Whitney U-test for non-normally distributed variables. Parameters (e.g., CO, fasting glucose, and hsCRP) were assessed by two-way ANOVA. Correlation analysis was performed to evaluate the relationship between the change in CO and the change in serum fasting glucose levels (or serum hsCRP levels) after adjustment for age, sex, current smoker, hypertension (yes/no), hyperlipidemia (yes/no), diabetes (yes/no), coronary artery disease (yes/no), HF (yes/no), NYHA class, body mass index, systolic blood pressure, diastolic blood pressure, estimated glomerular filtration rate, β-blocker (yes/no), and angiotensin-converting enzyme inhibitor (yes/no). The analyses were conducted in an intention-to-treat manner. The significance level was set at P < 0.05. Missing values were imputed by carrying the last observed value forward. Statistical analyses were performed using SPSS software version 18.0 (SPSS, Chicago, IL, USA).

**RESULTS**

**Patients**

A total of 78 patients with HF were screened in this study. Of these, 52 patients were eligible and randomized 1:1 to receive either liraglutide or placebo for 7 days, and 48 patients (92%) completed the trial (Figure 1). One patient had the diagnosis of de novo diabetes in the liraglutide group, and two patients had de novo diabetes diagnosed in the control group. Two patients had diabetic retinopathy in the liraglutide group, and one patient had diabetic retinopathy in the control group. No diabetic foot complications were found in the two groups. The clinical characteristics of the two groups are shown in Tables 1 and 2. There was no significant difference in age, sex, past medical history, hemoglobin levels, or creatinine levels between the two groups (Table 1). Furthermore, the use of β-blockers, aldosterone antagonists, and angiotensin-converting enzyme inhibitors was not significantly different between the two groups.

Hypoglycemia was reported in 1/26 (4%) patients in the control group and in 2/26 (8%) patients in the liraglutide group. Nausea occurred in 1/26 (4%) patients in the control group and in 2/26 (8%) patients in the liraglutide group. One patient had the diagnosis of de novo diabetes in the control group. No diabetic foot complications were found in the two groups (Table 1). Furthermore, the use of β-blockers, aldosterone antagonists, and angiotensin-converting enzyme inhibitors was not significantly different between the two groups.

**Hemodynamic variables**

At 7 days, the difference in change of CO (primary endpoint) between the liraglutide group and control group was +1.1 l/min (95% CI +0.1 to +2.2; P < 0.001) (Table 3 and Figure 2). In patients with a left ventricular ejection fraction (LVEF) < 30% at baseline (liraglutide group: n = 5; control group: n = 6), the difference in change of CO between the two groups after 7 days of treatment was +1.5 l/min (95% CI +0.2 to +2.9) (P < 0.001). The mean rise in the CI was significantly greater in the liraglutide group than in the control group (P < 0.001). Stroke volume was significantly higher in the liraglutide group compared with the control group (difference: +14.6 ml; P < 0.001). The difference in increase of dPmx after 7 days of treatment was +210.7 mmHg/s (liraglutide versus control groups, 95% CI 92.1 to +501.5; P < 0.001). However, the differences in changes in MAP and the GEDVI between the two groups were not significant.
LVEF measured by echocardiography significantly increased from 42.2% ± 7.1% to 51.2% ± 8.1% in the liraglutide group, and from 42.1% ± 7.3% to 45.6% ± 7.6% in the control group at day 7 (P < 0.001).

Fasting glucose, hsCRP, interleukin-6, SOD, malondialdehyde, NO, and NOS levels

Intention-to-treat analysis showed that fasting glucose levels decreased by 3.5 ± 1.6 mmol/L in the liraglutide group and by 2.3 ± 1.2 mmol/L in the control group from admission to the end of treatment (P = 0.01). The mean reduction in serum hsCRP levels was significantly greater in the liraglutide group than in the control group (Table 4). The difference in decrease in serum hsCRP levels between the liraglutide and control groups was −0.16 mg/dL (95% CI −0.20 to −0.11; P < 0.001). After 7 days of treatment, plasma SOD levels were higher and serum malondialdehyde levels were lower in the liraglutide group than in the control group. The difference in increase in serum SOD levels after 7 days of treatment was +14.2 U/mL (95% CI +4.4 to +26.2; P < 0.001). The change in CO was negatively correlated with the change in serum fasting glucose levels (r = −1.45, P = 0.02) and hsCRP levels (r = −0.75, P = 0.01) in adjusted analyses (Figure 3). There was also a correlation between the change in CO and the change in serum SOD levels (r = 0.18, P = 0.03).

When age, smoking, hypertension (yes/no), hyperlipidemia (yes/no), diabetes (yes/no), coronary artery disease (yes/no), HF (yes/no), NYHA class, body mass index, systolic blood pressure, diastolic blood

| Characteristics                  | Control group | Liraglutide group | p value |
|----------------------------------|--------------|------------------|--------|
| Age (years)                      | 58.7 ± 11.4  | 59.1 ± 11.8      | 0.90   |
| Male, n (%)                      | 19 (73%)     | 20 (77%)         | 0.75   |
| Current smoker, n (%)            | 17 (65%)     | 15 (58%)         | 0.57   |
| Past medical history             |              |                  |        |
| Hypertension, n (%)              | 16 (62%)     | 17 (65%)         | 0.77   |
| Hyperlipidemia, n (%)            | 3 (11%)      | 4 (15%)          | 1.00   |
| Diabetes mellitus, n (%)         | 7 (27%)      | 5 (19%)          | 0.51   |
| Coronary artery disease, n (%)   | 20 (77%)     | 21 (81%)         | 0.73   |
| Atrial fibrillation, n (%)       | 5 (19%)      | 6 (23%)          | 0.73   |
| Heart failure, n (%)             | 6 (23%)      | 7 (27%)          | 0.75   |
| NYHA classes, n (%)              |              |                  |        |
| I                                | 3 (12%)      | 2 (8%)           | 1.00   |
| II                               | 6 (23%)      | 7 (27%)          | 0.75   |
| III                              | 10 (38%)     | 9 (35%)          | 0.77   |
| IV                               | 7 (27%)      | 8 (30%)          | 0.76   |
| BMI (kg/m²)                      | 24.8 ± 3.8   | 25.3 ± 3.4       | 0.62   |
| Systolic blood pressure, (mmHg)  | 115 ± 13     | 118 ± 14         | 0.43   |
| Diastolic blood pressure, (mmHg) | 64 ± 15      | 65 ± 13          | 0.79   |
| Hemoglobin (g/dl)                | 13.3 ± 1.4   | 13.1 ± 1.3       | 0.59   |
| HbA1c (%)                        | 5.3 ± 0.4    | 5.4 ± 0.6        | 0.48   |
| Creatinine (mg/dl)               | 1.0 ± 0.1    | 1.0 ± 0.2        | 0.99   |
| eGFR (ml/min/1.73 m²)            | 83.5 ± 20.3  | 81.4 ± 19.5      | 0.71   |
| Medications, n (%)               |              |                  |        |
| ACEI                             | 15 (58%)     | 16 (62%)         | 0.78   |
| β-blocker                        | 20 (77%)     | 21 (81%)         | 0.73   |
| Furosemide                       | 6 (23%)      | 8 (31%)          | 0.53   |
| Aldosterone antagonist           | 11 (42%)     | 12 (46%)         | 0.78   |
| Digoxin                          | 4 (15%)      | 5 (19%)          | 0.71   |

Data are presented as mean value ± standard deviation or number or percentage (%) of patients. ACEI, angiotensin converting enzyme inhibitor; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin.
Table 2: Angiographical and procedural characteristics

| Characteristics                  | Control group (n = 20) | Liraglutide group (n = 21) | \( p \) value |
|----------------------------------|------------------------|----------------------------|--------------|
| Number of disease vessels, \( n (%) \) |                        |                            |              |
| Single vessel disease            | 4 (20%)                | 3 (15%)                    | 0.94         |
| Double vessel disease            | 10 (50%)               | 10 (47%)                   | 0.88         |
| Triple vessel disease            | 6 (30%)                | 8 (38%)                    | 0.58         |
| Culprit lesion, \( n (%) \)     |                        |                            |              |
| LAD                              | 10 (50%)               | 12 (57%)                   | 0.65         |
| RCA                              | 5 (25%)                | 4 (19%)                    | 0.93         |
| LCX                              | 5 (25%)                | 5 (24%)                    | 0.78         |
| PCI                              | 17 (85%)               | 19 (90%)                   | 0.95         |
| No. of stent per patients        | 1.7 ± 1.3              | 1.5 ± 1.4                  | 0.64         |
| CABG, \( n (%) \)                | 1 (5%)                 | 1 (5%)                     | 0.77         |

Data are presented as mean value ± standard deviation or number or percentage (%) of patients. LAD, left anterior descending artery; RCA, right coronary artery; LCX, left circumflex artery; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.

Figure 1: Patient flow chart.
pressure, and use of liraglutide were considered as explanatory variables, and improvement in CO was set as the dependent variable, administration of liraglutide was consistently identified as a significant determinant for improvement in CO using multivariate regression analysis ($P = 0.01$) (Table 5).

Events during the 3-month follow-up

During 3 months of follow-up, the incidence of MACE was not significantly lower in the liraglutide group than in the control group ($P > 0.05$). There were no significant differences in the incidence of myocardial infarction, hospitalization for HF, and cardiac death between the groups (Table 6).

DISCUSSION

We reported the effects of liraglutide on hemodynamic parameters in patients with HF. A significant difference in CO was observed between the two treatment groups. Additionally, liraglutide caused favorable changes in markers of inflammation and oxidative stress.

There are several important differences between our study and other studies [3, 5, 6, 16]. First, GLP-1 agonists have been extensively studied for improvement of...
cardiovascular function in preclinical and clinical models. The current study focused on hemodynamic parameters (CO, dPmx, GEDVI) in patients with HF at 7 days, while our previous study focused on LVEF in patients with acute myocardial infarction at 3 months [14, 15].

Second, a previous study by Nikolaidis et al. was short term and non-randomized [3]. The first randomized study of GLP-1 in HF by Halbirk et al. could not demonstrate an improvement in cardiac function [16]. Third, in our previous study, a short 7-day course of liraglutide in patients with non-ST-segment elevation myocardial infarction was associated with improvement in LVEF [14]. A 7-day treatment period was also chosen in the current study. Fourth, Nikolaidis et al. observed significant beneficial effects of GLP-1 on global LVEF in patients with and without diabetes [3]. We decided to choose liraglutide as the first choice of treatment in HF patients with and without diabetes. Fifth, the effect of liraglutide on LVEF was substantial in our study. Neither LIVE nor FIGHT showed a positive effect of liraglutide on LVEF [5, 6]. This difference in finding among studies might be related to the study population; patients with acute myocardial infarction were included in this study. Sixth, β-blockers, angiotensin-converting inhibitors, angiotensin-II receptor agonists, and diuretics are the cornerstone in HF treatment. Blood pressure was not high in patients in our study, and some patients did not receive an optimal dose of β-blockers or angiotensin-converting inhibitors. This could partly explain the discrepancy in findings between our study and recent studies of HF [5, 6]. Additionally, Kumarathurai found that liraglutide increased heart rate in patients with coronary artery disease after 12 weeks [17]. Long-term treatment of patients with type 2 diabetes with GLP-1 showed improvement in glycemic control.

### Table 4: Lab investigations of patients in two treatment groups

| Parameters                  | Control group          | Liraglutide group         | p value |
|-----------------------------|------------------------|---------------------------|---------|
|                             | Before treatment (n = 26) | Change in 7 days later control group | Before treatment (n = 26) | Change in 7 days later liraglutide group |        |
| Fasting blood glucose (mmol/L) | 8.5 ± 3.2 6.4 ± 1.5 | -2.3 (−3.5 to −1.5) | 8.6 ± 3.8 5.2 ± 1.8 | -3.5 (−5.5 to −1.8)* | 0.01 |
| Total cholesterol (mg/dL)   | 169.8 ± 25.6 151.8 ± 22.6 | 18.9 (−28.4 to −9.5) | 175.3 ± 34.5 152.7 ± 23.8 | -22.8 (−32.7 to −9.4) | 0.17 |
| Triglyceride (mg/dL)        | 92.2 ± 10.6 84.5 ± 10.8 | -8.4 (−13.6 to −3.5) | 92.8 ± 12.8 82.8 ± 9.5 | -9.5 (−15.6 to −5.5) | 0.43 |
| LDL cholesterol (mg/dL)     | 94.8 ± 22.7 82.7 ± 17.8 | -12.2 (−21.4 to −3.5) | 95.1 ± 22.8 77.3 ± 18.4 | -17.8 (−27.2 to −7.5) | 0.29 |
| NT-pro-BNP (pg/ml)          | 871.5 ± 338.6 216.8 ± 96.1 | -645.9 (−871.4 to −412.6) | 846.1 ± 384.6 95.5 ± 36.8 | -751.6 (−1061.2 to −465.5) | <0.001 |
| hsCRP (mg/dL)               | 1.08 ± 0.48 0.92 ± 0.38 | -0.18 (−0.25 to −0.08) | 1.06 ± 0.45 0.72 ± 0.35 | -0.35 (−0.48 to −0.19)* | <0.001 |
| Interleukin-6 (pg/mL)       | 14.7 ± 3.2 8.4 ± 2.5 | -6.8 (−9.5 to −3.4) | 15.2 ± 3.8 7.4 ± 2.5 | -7.9 (−11.4 to −3.2) | 0.27 |
| SOD (U/mL)                  | 105.7 ± 22.8 112.7 ± 21.5 | +5.6 (2.8 to 9.4) | 102.8 ± 21.4 124.5 ± 20.6 | +20.7 (9.5 to 32.8)* | <0.001 |
| Malondialdehyde (nmol/mL)  | 6.08 ± 1.84 6.02 ± 1.55 | -0.06 (−0.09 to −0.02) | 6.07 ± 1.93 5.92 ± 1.77 | -0.15 (−0.23 to −0.07)* | <0.001 |
| NO (umol/L)                 | 51.7 ± 8.4 59.4 ± 9.3 | +8.3 (3.5 to 12.8) | 52.1 ± 8.5 61.2 ± 9.2 | +9.5 (5.2 to 13.4) | 0.28 |
| NOS (U/mL)                  | 8.84 ± 0.14 9.85 ± 0.13 | +0.98 (0.52 to 1.38) | 8.95 ± 0.12 10.2 ± 0.18 | +1.11 (0.52 to 1.63) | 0.31 |

Values represent the mean ± standard deviation. *P < 0.05 liraglutide group vs. control group by 2-way ANOVA. LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; SOD, superoxide dismutase; NO, nitric oxide; NOS, nitric oxide synthase; NT-pro-BNP, N-terminal pro-brain natriuretic peptide.

**Figure 3:** (A) Changes in cardiac output (CO) correlated with changes in fasting glucose in liraglutide group at 7 days (n = 26). (B) Changes in cardiac output (CO) correlated with changes in high-sensitivity C-reactive protein in liraglutide group at 7 days (n = 26).
coupled with weight loss and lower blood pressure [18]. In our study, no effects of liraglutide on blood pressure and heart rate were observed in patients. These results may be partially explained by our short-term treatment with liraglutide.

The effects of GLP-1 on the cardiovascular system have been recently studied. A study in anesthetized pigs showed that pretreatment with GLP-1 decreased accumulation of lactate and pyruvate in ischemic myocardium, but had no effect on functional parameters [19]. In patients with type 2 diabetes and recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events [20]. However, Noyan-Ashraf et al. found that liraglutide significantly improved CO (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; \( P = 0.002 \)) in mice [21]. In our previous study, the difference in change in LVEF between the liraglutide group and the control group was +4.7% (95% CI +0.7% to +9.2% \( P = 0.009 \)) [14]. In the current study, CO was significantly higher in the liraglutide group compared with the control group. The difference in change of LVEF between the liraglutide group and control group was significant (+5.7%) in patients with HF. To the best of our knowledge, this is the first randomized trial to assess the effect of liraglutide in treatment of patients with HF using the PiCCO system.

Femoral artery dPmx provides reliable estimations of left ventricular systolic function [22]. Changes in dPmx accurately reflect changes in left ventricular contractile function in patients [23]. GLP-1 markedly improves post-ischemic cardiac contractile function in rats [24]. Poornima et al. found that chronic GLP-1 infusion improved left ventricular systolic function [25]. In our study, dPmx was also significantly increased in the liraglutide group. The transpulmonary thermodilution GEDVI behaves as an indicator of cardiac preload [26]. Some studies have suggested that GLP-1 stimulates solute-free water excretion by the human kidney and decreases fluid overload [27, 28]. Although the difference in change in the GEDVI between the liraglutide and control groups was not significant, the decrease observed in the liraglutide group was greater than that in the control group (−113.6 ± 301.2 ml/m² versus −60.5 ± 313.5 ml/m²).

### Potential mechanisms

Plasma glucose, blood pressure, and lipids are continuous variables that exert a dose-dependent effect on cardiovascular risk [29]. GLP-1 is an incretin hormone, which promotes myocardial glucose uptake [30]. GLP-1 might decrease glucose levels, improve cardiovascular risk, and enhance recovery of cardiac function [31]. HF is associated with inflammation and oxidative stress [32]. GLP-1 has been reported to ameliorate inflammation [33, 34]. Liraglutide might reduce inflammation and increase left ventricular contractile function and CO. GLP-1 can reduce oxidative stress [34]. Our results suggest that liraglutide might improve left ventricular function by reducing oxidative stress. This mechanism needs to be investigated in further studies.

### Table 5: Independent variables for the improvement in cardiac output

| Independent variables | Regression coefficient | hazard ratio (95% CI) | \( p \) value |
|-----------------------|------------------------|-----------------------|--------------|
| Age                   | −0.022                 | 0.95 (0.92–1.01)      | 0.28         |
| Smoking               | −0.215                 | 0.91 (0.82–1.21)      | 0.37         |
| Systolic blood pressure | −0.021               | 0.96 (0.86–1.11)      | 0.51         |
| Diastolic blood pressure | −0.016              | 0.82 (0.73–1.04)      | 0.57         |
| Administration of liraglutide | 2.177           | 1.64 (1.10–2.26)      | 0.01         |
| HsCRP                 | −0.622                 | 0.68 (0.37–0.81)      | 0.00         |
| Malondialdehyde      | −0.019                 | 0.95 (0.92–0.98)      | 0.03         |

hsCRP, high-sensitivity C-reactive protein.

### Table 6: Clinical outcome 3 months after initial treatment

|                          | Control group \((n = 26)\) | Liraglutide group \((n = 26)\) | \( p \) value |
|--------------------------|---------------------------|-------------------------------|--------------|
| MACE at 3 months, \( n \) (%)) | 5 (19%)                   | 3 (11%)                       | 0.70         |
| Myocardial infarction, \( n \) (%)) | 2 (7%)                    | 1 (4%)                        | 1.00         |
| Hospitalization for heart failure, \( n \) (%)) | 2 (7%)                    | 1 (4%)                        | 1.00         |
| Cardiac death, \( n \) (%)) | 1 (4%)                    | 0                             | 0.50         |

MACE, major adverse cardiovascular event.
Study limitations

This study has several limitations. First, the main limitation of this study is that it was from a single center and it had a small study size. Second, hemodynamic measurements were performed invasively with central venous and arterial catheters, and the results might be difficult to translate in routine clinical practice. Third, patients with moderate signs of HF were selected (i.e., ejection fraction < 50%). Therefore, data may be translated with difficulty to more severe conditions. Fourth, the genetic background should be considered. Some important polymorphisms are associated with endothelial dysfunction and coronary artery disease, including calcium/calmodulin-dependent kinase IV [35], glycoprotein IIIa PIA2 [36], and G-protein-coupled receptor kinases [37]. Fifth, liraglutide usually increases insulin secretion in hyperglycemia. Therefore, postprandial blood glucose and serum insulin levels should have been measured in our study.

CONCLUSIONS

GLP-1 may be associated with improvement in left ventricular function in patients with HF. This finding needs to be confirmed by larger invasive trials.

Authors’ contributions

All authors have substantially contributed to the manuscript in terms of conception and design, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content, and final approval of the version.

ACKNOWLEDGMENTS

We express our sincere appreciation to all participants in this study. We also thank Ping Jian Guo, Hang Yu, and Chang Fu Li, who assisted in this study

CONFLICTS OF INTEREST

The authors declare no potential conflicts of interest with respect to the research, authorship, or publication of this article.

FUNDING

The authors received no financial support for the research, authorship, or publication of this article.

REFERENCES

1. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001; 3:283–91.
2. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verhaan CW, Kerver M, Piek JJ, Doetendans PA, Pasterkamp G, Hoefer IE. Exemctin reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009; 53:501–10.
3. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109:962–5.
4. Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, Perticone M, Sesti G, Perticone F. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 2016. [Epub ahead of print].
5. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Möller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017; 19:69–77.
6. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom JK, Shah MR, et al. and NHLBI Heart Failure Clinical Research Network. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016; 316:500–8.
7. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011; 32:670–9.
8. Weissman A, Solt I, Zloczower M, Jakobi P. Hypoglycemia during the 100-g oral glucose tolerance test: incidence and perinatal significance. Obstet Gynecol. 2005; 105:1424–8.
9. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, and CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009; 150:604–12.
10. Best PJ, Reddan DN, Berger PB, Szczez LA, McCullough PA, Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J. 2004; 148:230–42.
11. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide—the FDA’s review of a new antidiabetic therapy. N Engl J Med. 2010; 362:774–7.
12. Kikugawa K, Kojima T, Yamaki S, Kosugi H. Interpretation of the thiobarbituric acid reactivity of rat liver and brain homogenates in the presence of ferric ion and ethyldiaminotetraacetic acid. Anal Biochem. 1992; 202:249–55.
13. Spöhr F, Hettrich P, Bauer H, Haas U, Martin E, Böttiger BW. Comparison of two methods for enhanced continuous circulatory monitoring in patients with septic shock. Intensive Care Medicine. 2007; 33:1805–10.
14. Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, Wang J, Yang JJ, Wang ZF, Tian F. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016; 52:516–26.

15. Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, Yang JJ, Wang ZF, Tian F, Ning QX. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2015; 170:845–54.

16. Halbirk M, Norrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjaer H, Botker HE, Wiggers H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol. 2010; 298:H1096–102.

17. Kumararthurai P, Anholm C, Larsen BS, Olsen RH, Madsbad S, Kristiansen O, Nielsen OW, Haugeard SB, Sajadieh A. Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care. 2017; 40:117–24.

18. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Rodigus IE. Evaluation of left ventricular function in anesthetized patients using femoral artery dP/dt(max). J Cardiothorac Vasc Anesth. 2006; 20:325–30.

19. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazzi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009; 58:975–83.

20. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Keber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, et al, and LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009; 32:1224–30.

21. Kommers M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikström G, Gutniak M. Glucagon-like peptide–1(7–36) amide prevents the accumulation of pyruvate and lactate in ischemic and non-ischemic myocardium. Peptides. 2003; 24:569–78.

22. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Koerber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, et al, and LEAD-4 Study Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373:2247–57.

23. DeHert SG, Robert D, Cromméecke S, Michaud F, Nijs J, Rodrigus IE. Evaluation of left ventricular function in anesthetized patients using femoral artery dP/dt(max). J Cardiothorac Vasc Anesth. 2006; 20:325–30.

24. Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Julivette L, Lepore JJ, Willette RN, DeAngelis E, Jucker BM. Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. Cardiovasc Diabetol. 2013; 12:148.

25. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail. 2008; 1:153–60.

26. Michaud F, Alaya S, Zarka V, Bahoul M, Richard C, Teboul JL. Global end-diastolic volume as an indicator of cardiac preload in patients with septic shock. Chest. 2003; 124:1900–8.

27. Shahamatova EI, Shutskaja ZV, Vladimirova ME, Garelov AI, Gorbunov AI, Natcchin IV. [Exenatide stimulated solute-free water excretion by human kidney]. [Article in Russian]. Ross Fiziol Zh Im I M Sechenova. 2012; 98:1021–9.

28. Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drews J, Gutmann H, Stanga Z, Vogel D, Beglinger C. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006; 73:142–50.

29. Santulli G. Coronary heart disease risk factors and mortality. JAMA. 2012; 307:1137.

30. Chen WR, Tian F, Chen YD, Wang J, Yang JJ, Wang ZF, Da Wang J, Ning QX. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol. 2016; 208:109–14.

31. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006; 317:1106–13.

32. Miranda H R, Castro G P, Verdejo P H, Chiong M, Díaz-Araya G, Mellado R, Rojas D, Concepción R, Lavandera S. [Oxidative stress and inflammation in heart failure: mechanisms of damage and therapeutic alternatives]. [Article in Spanish]. Rev Med Chil. 2007; 135:1056–63.

33. Dokken BB, La Borde LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011; 43:300–5.

34. Chang G, Zhang D, Yu H, Zhang P, Wang Y, Zheng A, Qin S. Cardioprotective effects of exenatide against oxidative stress-induced injury. Int J Mol Med. 2013; 32:1011–20.

35. Santulli G, Cipolletta E, Sorrentino D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A. CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc. 2012; 1:e001081.

36. Lammi F, Santulli G, Izzoro R, Rubattu S, Zanda B, Volpe M, Iaccarino G, Trimarco B. The PI3/A1/A2 receptor kinase 2 and hypertension: molecular insights and pathophysiologic mechanisms. High Blood Press Cardiovasc Prev. 2013; 20:5–12.